Sector News

Roche chairman sees opportunities for drugmakers under Trump

January 29, 2018
Life sciences

Fears U.S. President Donald Trump could damage the drugs industry have not been realized and the administration’s efforts to accelerate new medicine approvals will bolster the sector, the chairman of Swiss drugmaker Roche said.

“The U.S. Food and Drug Administration (FDA) wants to trim the time it takes for drugs to be approved,” Christoph Franz told Swiss newspaper Blick in an interview published on Friday.

“European regulators, when it comes to approving new medicines, are lagging the Americans by around six to 12 months. Europe has some catching up to do.”

FDA Commissioner Scott Gottlieb, whom Trump brought in, aims to approve drugs based on very early data if they show a possible survival benefit, among other measures to get medicines on the market faster.

After he was elected, Trump blasted drug companies, saying they had been “getting away with murder” with high prices.

While the Trump administration has since sought to change how hospitals are reimbursed for some drugs, his selection of Gottlieb, with deep ties to the drug industry, eased worries that he would seek a confrontation.

“Fears that Trump would damage the pharmaceuticals branch have not been realized,” Franz, who was in Davos for the World Economic Forum meeting, told Blick in the interview.

“It’s quite the opposite. We see new opportunities.”

By John Miller

Source: Reuters

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).